Samsara BioCapital

Samsara BioCapital investment thesis

Dr. Thomas is a physician scientist, immunologist with more than 20 years of experience in academia, large pharmaceutical companies and biotech across multiple diverse therapeutic areas. She has been a venture partner at Samsara BioCapital since 2023 and is currently an independent board director for Allakos Therapeutics and Ventus Therapeutics. She is also a scientific advisor for AnaptysBio. Prior to Samsara, she was a board director for Chinook (acquired by Novartis in 2023) and held multiple roles in biotech companies including Executive Vice President, Head of Research and Development and Chief Medical Officer at Equillium and the Chief Medical Officer of Principia Biopharma which was acquired by Sanofi September 2020 for 3.7 billion. Prior to biotech, Dr. Thomas held multiple roles i

Samsara BioCapital team (15)

Partners and principals at Samsara BioCapital:

• Srini Akkaraju — sweet spot $25M
• Aditya Asokan — sweet spot $25M
• Robert Baffi — sweet spot $25M
• Abe Bassan — sweet spot $25M
• John Curnutte — sweet spot $25M
• Mike Dybbs — sweet spot $25M
• Cory Freedland — sweet spot $25M
• Keith Gottesdiener — sweet spot $25M
• Perry Karsen — sweet spot $25M
• Marcos Milla — sweet spot $25M
• Steve Shuttleworth — sweet spot $25M
• Robert Stein — sweet spot $25M
• Mani Subramanian — sweet spot $25M
• Nate Tower — sweet spot $25M
• Roger Zhang — sweet spot $25M

Samsara BioCapital portfolio companies

Companies listed on Samsara BioCapital's public materials include: SAMSARA BIOCAPITAL, Culture, Team, Portfolio, Investor Portal, Srini’s Take, Our Portfolio, A2 Biotherapeutics, Inc., Go to website, Abcuro, Inc., IPO, Abivax SA, Acelyrin, Inc, Alamar Biosciences, Inc., Alentar, Allakos, Inc., Alpha-9 Oncology, Inc., Alpheus, Alumis, Inc., Arcellx, Inc., Cold Start Therapeutics, Autobahn Labs, LLC, Autobahn Therapeutics, Bionic Sight, Inc., Bolt Biotherapeutics, Inc., CARGO Therapeutics, Acquired , IPO*, Chinook Therapeutics, Codex Health, Inc., Contineum Therapeutics, Acquired , IPO, Decibel Therapeutics, Candid Therapeutics, Delfi Diagnostics, Inc., DewPoint Therapeutics, Inc., Acquired, DICE Therapeutics, ElevateBio, LLC, Enara Bio, Ltd., Enlaza Therapeutics, Inc., Epibiologics, Exo Therapeutics, Inc., Excellergy Therapeutics, Eyebiotech Limited, Fluent Biosciences, Inc., Forma Therapeutics, Genalyte, Inc., Gossamer, Hillevax, Inc., IntegerBio, Inc., Intercept Pharmaceuticals, Inventiva, IO Biotech, Inc., Iveric Bio, Janux Therapeutics, Inc., IPO*, Kalaris Therapeutics, Inc. (F/K/A Theia), LENZ Therapeutics, Inc., Link Cell Therapies Inc., Maro Bio.

Is Samsara BioCapital a fit for your round?

Upload your pitch deck and see whether anyone at Samsara BioCapital appears in your top matches.